Multiple Sclerosis

MS-Related Fatigue Reduced With Transcranial Direct Current Stimulation

By October 04, 2017

Fatigue was assessed using the Patient-Reported Outcomes Measurement Information System.

Mylan Gets Approval for Generic Versions of Two Copaxone Strengths

By October 04, 2017

The mechanism by which glatiramer acetate exerts its therapeutic effect in MS is unknown, however it is thought to act by modifying immune processes that are believed to be responsible for the pathogenesis of MS.

Vit D Deficiency: A Risk Factor for MS?

By September 21, 2017

Data showed that a 50nmol/L increase in 25(OH)D correlated with a 39% decreased risk of MS. Specifically, a 43% increased risk of MS was seen in women with 25(OH)D levels <30nmol/L vs. women with levels ≥50nmol/L.

Multiple Sclerosis Treatment Highlights

By September 13, 2017

MPR interviewed Dr. John Stoffel to discuss the strategies for diagnosis and management of urinary retention in MS patients, as well as his recommendations for optimal care for these patients.

Epstein-Barr Virus May Increase Risk for Multiple Sclerosis

August 31, 2017

The researchers found that those with MS in all three racial groups were more likely to show signs of infection with EBV.

Dimethyl Fumarate and Oral Contraceptives: Drug Interactions Explored

By August 08, 2017

Delayed-release DMF exerts anti-inflammatory and neuroprotective properties for the treatment of relapsing multiple sclerosis, a disease that often develops in women between the ages of 20 and 40.

MS Risk May Be Lower for Mothers Who Breastfeed

July 13, 2017

Benefits reported for women who nursed 15 months or more

Ocrevus Effective in Reducing Multiple MS Progression Markers

By June 23, 2017

The post-hoc analyses found Ocrevus to significantly decrease disease activity and disability progression in patients with RMS and PPMS, as assessed by No Evidence of Progression or Active Disease (NEPAD), a new composite endpoint in MS.

Brain Changes in MS Linked to Social Cognition Impairment

June 02, 2017

Diffuse normal-appearing white matter damage may create disconnection in social brain network

Minocycline May Benefit in Early Multiple Sclerosis

June 01, 2017

Treatment with minocycline reduces conversion to MS over six months after first demyelinating event

FDA Approves App to Help Guide MS Patient Care with Betaseron

By May 31, 2017

This new software allows patients currently using the electronic BETACONNECT autoinjector to administer Betaseron (interferon beta-1b) to connect their autoinjector to the new myBETAapp through their mobile device or computer.

Novel Oral Therapy Looks Promising for Relapsing MS

By May 22, 2017

The Radiance trial included 1,313 relapsing multiple sclerosis (RMS) patients who were administered either 0.5mg or 1mg of oral ozanimod, or weekly intramuscular interferon beta-1a (Avonex) over a 2 year treatment period.

Pharmacist Program Demonstrates Benefits for MS Patients

May 17, 2017

Cheong noted that only 1 patient was non-adherent. There was an increase in patient knowledge scores, from a mean baseline score of 20.14 to 31.67 (P<0.05) by the end of the third appointment.

Additional Data Support Ocrevus Safety, Efficacy in MS

By April 27, 2017

Among patients with early relapsing multiple sclerosis patients, Ocrevus suppressed >90% of active MRI lesions over 2 years vs. interferon beta-1a.

Long-Term Data Show Benefits of Lemtrada in RRMS

By April 26, 2017

The majority of patients who relapsed between courses were free of confirmed disability worsening (CDW) in Year 2 and 60% remained free of CDW by Year 6.

Aubagio Reduces Cortical Gray Matter Atrophy in MS Study

By April 26, 2017

Study patients treated with Aubagio 14mg and 7mg had a significantly reduced risk of developing clinically definite MS vs. placebo (P<0.05).

Altered T-Cell Infusions Show Promise in Patients With Progressive MS

April 21, 2017

Over 6 months, the researchers said, none of the patients suffered serious side effects from the treatment. In addition, 3 showed symptom improvements within 2 to 8 weeks of their first T-cell infusion.

Is Maternal Health During Pregnancy Tied to Offspring MS Risk?

March 31, 2017

The researchers found that maternal illness during pregnancy correlated with 2.3-fold increased odds of having mulitple sclerosis.

Ocrevus Approved for Relapsing, Primary Progressive MS

By March 29, 2017

This is the first drug approved for primary progressive MS.

Controversial Therapy Found to Be Ineffective for MS

March 09, 2017

Invasive procedure carries risk of complications, significant financial cost, researcher says

Autoimmune Diseases and Risk of Dementia, CVD, and Stroke Onset

March 03, 2017

Patients with autoimmune diseases appear to have an increased risk of developing dementia, according to a study published online March 1 in the Journal of Epidemiology & Community Health.

Certain MS Patients May Benefit from Stem Cell Transplantation

February 23, 2017

Results support additional trials of autologous hematopoietic stem cell transplantation

Novel Oral MS Drug Effective, Safe in Phase 3 Study

By February 21, 2017

The primary endpoint was the reduction of annualized relapse rate (ARR) during the treatment period.

Investigational Tx Shows Efficacy in Reducing Brain Atrophy in RRMS

By February 09, 2017

The investigational multiple sclerosis (MS) therapy cladribine tablets (Merck) has shown efficacy in reducing annualized rate of brain atrophy when compared to placebo in patients with relapsing remitting multiple sclerosis (RRMS).

MS Outcomes Investigated with Ocrelizumab

December 22, 2016

Studies show lower relapse rate in relapsing MS, lower rate of progression in primary progressive dz

Infant Vitamin D Levels Linked to Later Life MS Development

December 02, 2016

Infants born with low levels of vitamin D may be more likely to develop multiple sclerosis later in life

REMS Requirement Lifted for MS Drug

December 01, 2016

The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Gilenya (fingolimod; Novartis) capsules regarding its Risk Evaluation and Mitigation Strategy (REMS) assessment.

Alemtuzumab May Improve Pre-existing Disability in MS Patients

October 17, 2016

The multiple sclerosis (MS) drug alemtuzumab, usually reserved for patients in the late stages of the disease, seems to offer long-term remission in newly diagnosed patients, according to a study published online October 12 in Neurology.

MS Treatment Strategies: A Review of Disease-Modifying Therapies

By October 14, 2016

Multiple factors may indicate the use of aggressive treatment.

Natalizumab Compared to Fingolimod in Relapsing-Remitting MS

By October 04, 2016

Until this study, natalizumab and fingolimod have never been directly compared in a randomized clinical trial.